Alk-Abello A/S (Alk-Abello A/S) Gross-Profit-to-Asset % : 52.55% (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Alk-Abello A/S Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Alk-Abello A/S's annualized Gross Profit for the quarter that ended in Mar. 2024 was $518.4 Mil. Alk-Abello A/S's average Total Assets over the quarter that ended in Mar. 2024 was $986.5 Mil. Therefore, Alk-Abello A/S's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 52.55%.

Alk-Abello A/S Gross-Profit-to-Asset % Historical Data

The historical data trend for Alk-Abello A/S's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello A/S Gross-Profit-to-Asset % Chart

Alk-Abello A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

36.10

38.40

40.55

44.55

47.18

Alk-Abello A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															50.73	44.40	41.72	51.35	52.55

Competitive Comparison of Alk-Abello A/S's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Alk-Abello A/S's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alk-Abello A/S's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello A/S's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Alk-Abello A/S's Gross-Profit-to-Asset % falls into.

Alk-Abello A/S Gross-Profit-to-Asset % Calculation

Alk-Abello A/S's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	444.051	/	( (898.204	+	984.081)	/ 2 )
	=	444.051	/	941.1425
	=	47.18 %

Alk-Abello A/S's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	518.384	/	( (984.081	+	988.95)	/ 2 )
	=	518.384	/	986.5155
	=	52.55 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Alk-Abello A/S Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Alk-Abello A/S's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alk-Abello A/S (Alk-Abello A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello A/S (OTCPK:AKBLF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

ALKBc:UK 0OIR:UK ALK B:Denmark 4AJ0:Germany

Address

Boge Alle 6-8, Horsholm, DNK, DK-2970

Website

https://www.alk.net

Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication.